Regeneron Pharmaceuticals’ Eylea (aflibercept) treatment for central retinal vein occlusion (CRVO) has been approved by the European Commission.
Eylea was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2011, and for macular edema following CRVO in 2012. The drug has also been approved in Europe, Japan, Australia, and in several other countries for use in wet AMD and in selected countries in South American for macular edema following CRVO. More about this approval…
